Could a Treatment for ALS Be in Sight? The Secret of a Protein That Kills Neurons Revealed [Health LAB]
- Input
- 2026-11-19 05:00:00
- Updated
- 2026-11-19 05:00:04

[Financial News] The mechanism by which a protein destroys neurons in patients with brain diseases such as ALS has been uncovered. The findings raise hopes that it could be used as a treatment strategy for neurodegenerative brain diseases.
According to the Korea Brain Research Institute (KBRI) on the 19th, a team led by senior researchers Kim Jae-gwang and Nam Min-yeop of its Brain Disease Research Department identified a new pathway by which TDP-43 protein aggregates, commonly observed in ALS and frontotemporal dementia, kill neurons.
The study was conducted in collaboration with research teams led by Principal Researcher Kim Cheon-a of the Korea Research Institute of Bioscience and Biotechnology (KRIBB), Professor Lee Sang-won of Korea University, and Professor Kim Sang-ryong of Kyungpook National University. The findings were published in the international journal Redox Biology (IF 16.2, ranked in the top 3.2% in the JCR category of BIOCHEMISTRY & MOLECULAR BIOLOGY).
TDP-43 is a protein that normally regulates the processing of genetic information in the cell nucleus so it can be used smoothly to produce proteins. In disease, however, it moves from the nucleus into the cytoplasm and forms aggregates, creating clumps of protein. These TDP-43 aggregates are observed in about 97% of ALS patients and about half of patients with frontotemporal dementia, but how the clumps kill neurons has not been fully understood.
The research team focused on thioredoxin-1 (Trx1), a major antioxidant protein in cells. Trx1 removes reactive oxygen species in cells and helps restore oxidized proteins. The team found that it is a key link connecting mitochondrial dysfunction and redox imbalance to TDP-43 neurotoxicity.
In other words, TDP-43 aggregated in the cytoplasm trapped messenger RNA (mRNA), which carries the genetic information needed to produce Trx1, inside insoluble aggregates, inhibiting protein production. The team confirmed that this leads to neuronal toxicity through increased oxidative stress and mitochondrial dysfunction.
Increasing Trx1 in mouse neurons reduced TDP-43 aggregation and neurotoxicity. In addition, when Trx1 expression was increased in motor neurons derived from induced pluripotent stem cells of a person with an ALS-related TDP-43 genetic mutation, oxidative stress and aggregation decreased significantly. In other words, the team confirmed that this protective effect was also maintained in human cells.
Dr. Kim Jae-gwang of the Korea Brain Research Institute, who led the research team, said, “This shows that TDP-43 aggregates are not merely traces of disease, but active perpetrators that directly disable the cell’s defense system.” He added, “We hope that restoring Trx1 will lead to a new treatment strategy for TDP-43-related neurodegenerative brain diseases, including ALS.”
[email protected] Yeon Ji-an Reporter